Discover
VRNA
Verona Pharma plc
106.91
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 130.21% | |
| 1y | 233.99% |
106.91
day range
106.91
31.60
52 week range
106.93
| Open | 106.85 | Prev Close | 106.91 | Low | 106.91 | High | 106.91 | Mkt Cap | 9.09B |
| Vol | 1.87M | Avg Vol | 1.69M | EPS | -1.04 | P/E | N/A | Forward P/E | -381.82 |
| Beta | 0.05 | Short Ratio | 1.56 | Inst. Own | 92.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 105.95 | 200-d Avg | 79.84 | 1yr Est | 0.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-03 | 2025-09 | 0.16 | N/A | N/A | N/A |
| 2025-08-06 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-04-29 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-02-27 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-11-04 | 2024-09 | 0 | N/A | N/A | N/A |
| 2024-08-08 | 2024-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-07-14 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2025-07-10 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| 2025-07-10 | BTIG | Downgrade | Buy | Neutral |
| 2025-07-09 | Jefferies | Downgrade | Buy | Hold |
| 2025-07-09 | Canaccord Genuity | Downgrade | Buy | Hold |
| 2025-07-01 | Wolfe Research | Upgrade | Outperform |
Profile
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-10-06 | ACKERMANN CHRISTINA M | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-10-06 | AUSTWICK MICHAEL | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-10-06 | DESCHAMPS LISA | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-10-06 | EDWARDS MARTIN | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-10-06 | HAHN MARK W | Chief Financial Officer | 0.00 | Conversion of Exercise of derivative security |
| 2025-10-06 | RICKARD KATHLEEN A | Officer | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | Janus Henderson Group PLC | 6.13M | 655.83M | 7.12% |
| 2025-06-29 | Perceptive Advisors Llc | 5.51M | 588.82M | 6.39% |
| 2025-06-29 | Darwin Global Management, Ltd. | 4.13M | 441.50M | 4.79% |
| 2025-06-29 | Frazier Life Sciences Management, L.P. | 3.38M | 361.78M | 3.93% |
| 2025-06-29 | RTW Investments LP | 3.05M | 326.28M | 3.54% |
| 2025-06-29 | Eventide Asset Management LLC | 2.72M | 290.30M | 3.15% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 1.89M | 202.02M | 2.19% |
| 2025-06-29 | T. Rowe Price Health Sciences Fund, Inc. | 1.36M | 145.08M | 1.57% |
| 2025-06-29 | JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 936.80K | 100.15M | 1.09% |
| 2025-07-30 | Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 820.64K | 87.74M | 0.95% |
| 2025-06-29 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 809.11K | 86.50M | 0.94% |
| 2025-06-29 | Putnam Funds Trust-Putnam Small Cap Growth Fund | 734.13K | 78.49M | 0.85% |